REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$765.19

Market cap

$83.33B

P/E Ratio

15.21

Dividend/share

N/A

EPS

$50.31

Enterprise value

$82.54B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The quick ratio has grown by 44% YoY and by 4% from the previous quarter
The equity has grown by 24% year-on-year and by 3.6% since the previous quarter
REGN's price to earnings (P/E) is 43% higher than its last 4 quarters average of 10.6 but 12% lower than its 5-year quarterly average of 17.3
The company's EPS fell by 24% YoY and by 6% QoQ
Regeneron Pharmaceuticals's net income has decreased by 23% YoY and by 6% QoQ

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
108.9M
Market cap
$83.33B
Enterprise value
$82.54B
Valuations
Price to earnings (P/E)
15.21
Price to book (P/B)
3.89
Price to sales (P/S)
5.97
EV/EBIT
13.55
EV/EBITDA
12.88
EV/Sales
6.02
Earnings
Revenue
$13.71B
EBIT
$6.09B
EBITDA
$6.41B
Free cash flow
$5.07B
Per share
EPS
$50.31
Free cash flow per share
$47.47
Book value per share
$196.67
Revenue per share
$128.25
TBVPS
$251.39
Balance sheet
Total assets
$27.68B
Total liabilities
$6.24B
Debt
$2.7B
Equity
$21.44B
Working capital
$12.55B
Liquidity
Debt to equity
0.13
Current ratio
5.36
Quick ratio
4.37
Net debt/EBITDA
-0.12
Margins
EBITDA margin
46.7%
Gross margin
85.4%
Net margin
39.2%
Operating margin
45.5%
Efficiency
Return on assets
20.1%
Return on equity
26.6%
Return on invested capital
26.9%
Return on capital employed
24.6%
Return on sales
44.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.12%
1 week
0.52%
1 month
1.76%
1 year
16.99%
YTD
21.17%
QTD
11.08%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$13.71B
Gross profit
$11.71B
Operating income
$6.23B
Net income
$5.37B
Gross margin
85.4%
Net margin
39.2%
The net margin has decreased by 24% YoY and by 2% from the previous quarter
Regeneron Pharmaceuticals's net income has decreased by 23% YoY and by 6% QoQ
Regeneron Pharmaceuticals's operating margin has decreased by 18% YoY and by 6% QoQ
The operating income fell by 17% YoY and by 9% QoQ

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
15.21
P/B
3.89
P/S
5.97
EV/EBIT
13.55
EV/EBITDA
12.88
EV/Sales
6.02
REGN's price to earnings (P/E) is 43% higher than its last 4 quarters average of 10.6 but 12% lower than its 5-year quarterly average of 17.3
The company's EPS fell by 24% YoY and by 6% QoQ
The equity has grown by 24% year-on-year and by 3.6% since the previous quarter
REGN's price to book (P/B) is 15% less than its 5-year quarterly average of 4.6 but 11% more than its last 4 quarters average of 3.5
The P/S is 30% higher than the last 4 quarters average of 4.6 but 5% lower than the 5-year quarterly average of 6.3
The revenue has decreased by 3.6% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has decreased by 47% YoY and by 10% QoQ
Regeneron Pharmaceuticals's return on invested capital has decreased by 43% YoY and by 9% QoQ
The return on assets has declined by 42% year-on-year and by 9% since the previous quarter
The company's return on sales fell by 26% YoY

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The quick ratio has grown by 44% YoY and by 4% from the previous quarter
The current ratio is up by 44% YoY and by 4.7% QoQ
The debt is 87% less than the equity
The equity has grown by 24% year-on-year and by 3.6% since the previous quarter
REGN's debt to equity is down by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.